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ABSTRACT
ObjectiveToexaminetheeffectofprotonpumpinhibitors
on adverse cardiovascular events in aspirin treated
patients with first time myocardial infarction.
Design Retrospective nationwide propensity score
matched study based on administrative data.
Setting All hospitals in Denmark.
ParticipantsAll aspirin treatedpatientssurviving 30 days
after a first myocardialinfarction from1997 to 2006, with
follow-up for one year. Patients treated with clopidogrel
were excluded.
Main outcome measures The risk of the combined end
point of cardiovascular death, myocardial infarction, or
strokeassociatedwithuseofprotonpumpinhibitorswas
analysed using Kaplan-Meier analysis, Cox proportional
hazard models, and propensity score matched Cox
proportional hazard models.
Results 3366 of 19925 (16.9%) aspirin treated patients
experienced recurrent myocardial infarction, stroke, or
cardiovascular death. The hazard ratio for the combined
end point in patients receiving proton pump inhibitors
based on the time dependent Cox proportional hazard
model was 1.46 (1.33 to 1.61; P<0.001) and for the
propensityscore matched modelbased on8318 patients
it was 1.61 (1.45 to 1.79; P<0.001). A sensitivity analysis
showed no increase in risk related to use of H2 receptor
blockers (1.04, 0.79 to 1.38; P=0.78).
Conclusion In aspirin treated patients with first time
myocardial infarction, treatment with proton pump
inhibitors was associated with an increased risk of
adverse cardiovascular events.
INTRODUCTION
The possible interactions between antithrombotic
drugsandprotonpumpinhibitorsresultinginreduced
antithrombotic effect and increased cardiovascular
risk for patients receiving combination therapy has
received much attention. Particular attention has
been given to the interaction between clopidogrel
and proton pump inhibitors, but an interaction
between aspirin and proton pump inhibitors has also
been proposed.
Aspirin inhibits platelet aggregation and remains a
cornerstone in the management of atherothrombotic
disease,
12despite the questionable net value of aspirin
treatmentinprimaryprevention.
3Owingtothegastro-
intestinal side effects associated with aspirin, proton
pump inhibitors are widely used for the prevention of
pepticulcersinpatientstreatedwithaspirin,andguide-
lines advocate the use of proton pump inhibitors in a
wide group of patients treated with aspirin after myo-
cardialinfarction.
4Ithasbeensuggested,however,that
treatmentwithprotonpumpinhibitorsmayreducethe
bioavailability of aspirin, resulting in reduced platelet
inhibition.
5Protonpumpinhibitorsexertasuppressive
effect on the production of gastric acid and therefore
havethepotentialtoaltertheextentofdrugabsorption
through modification of intragastric pH. The results of
recentstudiesonwhethertreatmentwithprotonpump
inhibitorssignificantlyinfluencesaspirininducedinhi-
bition of platelet aggregation have been conflicting.
67
We studied a large unselected cohort of patients
admittedtohospitalwithafirstevermyocardialinfarc-
tion,withparticularfocusontheriskofadversecardio-
vasculareventsassociatedwithconcomitanttreatment
with aspirin and proton pump inhibitors.
METHODS
We carried out a retrospective complete nationwide
study based on information from four Danish national
registers.EveryresidentinDenmarkisprovidedwitha
permanent and unique civil registration number at
birth, enabling linkage between registers at individual
level.Immigrantsareassignedacivilregistrationnum-
ber when they are registered as residents. We com-
bined data on primary admissions to hospital,
pharmacy prescription claims, subsequent admissions
to hospital, and deaths for 3.7 million people.
TheDanishnationalpatientregistryregistersallhos-
pitaladmissionsinDenmarkwithoneprimarydiagno-
sis and, if appropriate, one or more secondary
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Diseases. The national prescription registry keeps
records of every prescription dispensed from pharma-
cies in Denmark, with each drug being classified
accordingtothe internationalAnatomicalTherapeuti-
cal Chemicalsystem.TheDanishcivilregistryandthe
national causes of death registry keep information on
vital status and causes of death.
Patients
Weidentifiedallconsecutivepatients,aged30yearsor
more, admitted to hospital with a first myocardial
infarction (ICD-10 codes I21-I22) as a primary or sec-
ondary diagnosis between 1997 and 2006. We
excluded patients treated with clopidogrel owing to
the recent controversy related to the effects of its use
with proton pump inhibitors. The study therefore
included patients treated only with aspirin. Patients
were identified according to claimed prescriptions
within 30 days from discharge. To ensure equal time
for all patients to claim prescriptions for aspirin and to
minimise the risk of immortal time bias, we only
included patients surviving 30 days after discharge.
We excluded patients with partially missing data, and
patients emigrating were censored at the time of emi-
gration. Income group was defined by the individual
average yearly gross income during a five year period
before study inclusion, and patients were divided into
fifths according to their income.
Drug use
Information on concomitant drug use was based on
claimed prescriptions in the 90 days after discharge
(180 days for statins),
8 except for information on use
of proton pump inhibitors, H2 receptor blockers, and
non-steroidal anti-inflammatory drugs, which was
based on all claimed prescriptions within one year
after discharge. The information included dispensing
date; drug type, quantity, and dose; and days of drug
supply, but did not contain data on patient reported
adherence. We defined current use as the period
from the date the prescription was filled to the calcu-
lated end of the drug supply period. The national pre-
scription register has been shown to be accurate.
9 The
standard dose of aspirin after myocardial infarction in
Denmark is 75 mg once daily.
Outcomes
The primary outcome was the combined end point of
death from cardiovascular causes and readmission to
hospital for myocardial infarction or stroke. Secondary
outcomes were all cause death, cardiovascular death,
and readmission to hospital for myocardial infarction
or stroke. Follow-up was one year after discharge. The
diagnoses of acute myocardial infarction and stroke
have been validated in the national patient registry.
1011
Comorbidity
We defined comorbidity from diagnoses at discharge
aftertheindexmyocardialinfarctionasspecifiedinthe
Ontario acute myocardial infarction mortality predic-
tion rule.
12 The comorbidity index was further opti-
mised by adding diagnoses from the year before the
event, as previously described.
13
To define high risk subgroups of patients, we used
the concomitant use of loop diuretics or drugs for dia-
betes as a proxy for heart failure and diabetes, respec-
tively.
Statistical analyses
Baselinecharacteristicsarepresentedasnumbers(per-
centages) for categorical variables and as means (stan-
dard deviations) for continuous variables. We used
Kaplan-Meier estimates to generate time to event
curves for the primary end point.
To consolidate the strength of our findings we used
two statistical methods to estimate the risk associated
with treatment using proton pump inhibitors. Firstly,
we constructed Cox proportional hazards models to
derive hazard ratios and 95% confidence intervals.
We adjusted the models for age, sex, year of inclusion,
percutaneous coronary intervention, income group,
concomitant medical treatment, and comorbidity.
Use of proton pump inhibitors was included as a time
dependent covariate. Secondly, we carried out a pro-
pensityscorematchedCoxproportionalhazardanaly-
sis.Wequantifiedapropensityscoreforthelikelihood
of receiving proton pump inhibitors within the first
yearfromdischargeby multivariate logisticregression
analysisconditionalonbaselinecovariates(seetable 1).
Using the Greedy matching macro (http://mayore
search.mayo.edu/mayo/research/biostat/upload/
gmatch.sas) we matched each case to one control on
the basis of the propensity score. Use of proton pump
inhibitors during follow-up was again included as a
time dependent covariate.
Tofurtherassesstherobustnessofourresultswedid
a series of additional analyses, including an analysis
using the method by Schneeweiss that evaluates how
large the effect of an unmeasured confounder or com-
bination of confounders would need to be account for
the results,
14 together with analysis of high risk patient
subgroups, analysis dependent on subtype of proton
pumpinhibitor,adosedependentanalysis,andanana-
lysis of the effect of concomitant use of non-steroidal
anti-inflammatory drugs. Statistical calculations were
carried out with SAS version 9.2.
RESULTS
A total of 97499 adults over the age of 30 were
admitted with a first myocardial infarction during
1997 to 2006 (fig 1). Of these, 48047 were excluded:
19215 patients died before or within 30 days of dis-
charge, 28673 were treated with clopidogrel, and 159
had partially missing data. Of the remaining 49452
patients, 19925 filled a prescription for aspirin within
30 days and comprised the study cohort. Of these,
4306 (21.6%) claimed at least one prescription for pro-
ton pump inhibitors and 661 (3.3%) filled at least one
prescription for H2 receptor blockers within one year
ofdischarge.Table 1showsthebaselinecharacteristics
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pump inhibitors were older, more often female,
received more concomitant medical treatment, and
had more comorbidity than patients not treated with
proton pump inhibitors. Baseline characteristics were
balanced in the propensity matched populations.
Outcomes
During the year of follow-up, 3365 (16.9%) cardio-
vascular deaths and readmissions to hospital for myo-
cardial infarction or stroke and 2293 (11.5%) all cause
deaths occurred. Table 2 shows the distribution of
events.
Time dependent analyses
The multivariate time dependent Cox proportional
hazards regression analysis yielded a hazard ratio of
1.46 (95% confidence interval 1.33 to 1.61; P<0.001)
for the composite end point in patients receiving pro-
ton pump inhibitors compared with those not treated
withprotonpumpinhibitors.Theresultsforsecondary
outcomes were similar (table 2).
Using propensity score, 4159 patients treated with
aspirin and proton pump inhibitors were matched
with an equal number of patients not treated with pro-
ton pump inhibitors. Table 2 shows the baseline char-
acteristicsofthepropensityscorematchedpopulations
and P values for differences between the groups and
table 3 gives details of the matching (also see web
extra table 1 and fig 1). Treatment compared with no
treatment with proton pump inhibitors yielded a
hazard ratio for cardiovascular death and readmission
Table 1 Baseline characteristics and propensity score matched baseline characteristics at inclusion. Values are numbers (percentages) unless stated
otherwise
Characteristics
Baseline Propensity score matched baseline
Patients not treated
with PPIs (n=15 619)
Patients treated
with PPIs (n=4306)
P value for
difference
Patients not treated
with PPIs (n=4159)
Patients treated
with PPIs (n=4159)
P value for
difference
Mean (SD) age (years) 69.9 (13.0) 72.7 (12.3) <0.001 72.7 (12.6) 72.5 (12.1) 0.48
Men 9638 (61.7) 2318 (53.8) <0.001 2212 (53.2) 2242 (53.9) 0.51
Income group: <0.001 0.71
0 3331 (21.3) 888 (20.6) 893 (21.5) 857 (20.6)
1 3196 (20.5) 1056 (24.5) 999 (24.0) 1002 (24.1)
2 3007 (19.3) 980 (22.8) 936 (22.5) 949 (22.8)
3 3171 (20.3) 8123 (18.9) 752 (18.1) 791 (19.0)
3 2914 (18.7) 570 (13.2) 579 (13.9) 560 (13.5)
Percutaneous coronary intervention 879 (5.6) 253 (5.9) 0.53 235 (5.7) 249 (6.0) 0.51
Medical condition:
Shock 116 (0.7) 74 (1.7) <0.001 53 (1.3) 61(1.5) 0.45
Diabetes with complications 721(4.6) 244 (5.7) 0.005 192 (4.6) 231(5.6) 0.05
Peptic ulcer 68 (0.4) 186 (4.3) <0.001 68 (1.6) 72 (1.7) 0.73
Pulmonary oedema 193 (1.2) 62 (1.4) 0.29 59 (1.4) 59 (1.4) 1.00
Cerebral vascular disease 647 (4.1) 276 (6.4) <0.001 240 (5.8) 255 (6.1) 0.49
Cancer 61 (0.4) 27 (0.6) 0.04 19 (0.5) 25 (0.6) 0.36
Cardiac arrhythmias 1646 (10.5) 547 (12.7) <0.001 492 (11.8) 520 (12.5) 0.35
Acute renal failure 75 (0.5) 73 (1.7) <0.001 49 (1.2) 54 (1.3) 0.62
Chronic renal failure 103 (0.7) 116 (2.7) <0.001 86 (2.1) 91 (2.2) 0.70
Prescribed drugs:
Loop diuretics 7015 (44.9) 2467 (57.3) <0.001 2346 (56.4) 2365 (56.9) 0.67
Spironolactone 1374 (8.8) 577 (13.4) <0.001 510 (12.3) 556 (13.4) 0.13
Statins 6920 (44.3) 1960 (45.5) 0.16 1953 (47.0) 1907 (45.9) 0.31
β blockers 11 157 (71.4) 2993 (69.5) 0.01 2926 (70.4) 2891 (69.5) 0.40
ACE inhibitors 6553 (42.0) 1890 (43.9) 0.02 1891 (45.5) 1829 (44.0) 0.17
Antidiabetes drugs 1847 (11.8) 513 (14.2) <0.001 531 (12.8) 587 (14.1) 0.07
Vitamin K antagonist 1169 (7.5) 353 (8.2) 0.12 318 (7.7) 343 (8.3) 0.31
PPIs=proton pump inhibitors; ACE=angiotensin converting enzyme.
Adults aged >30 admitted with first
myocardial infarction 1997-2006 (n=97 499)
Patients who filled prescription for aspirin
within 30 days of discharge (n=19 925)
Patients who filled
prescription for proton pump
inhibitor within one year
of discharge (n=4306)
Patients who did not fill
prescription for proton pump
inhibitor within one year
of discharge (n=15 619)
Patients excluded (n=77 574):
  Dead before or within 30 days of discharge (n=19 215)
  Did not fill prescriptions for aspirin within 30 days of
    discharge (n=29 527)
  Filled prescriptions for clopidogrel (n=28 673)
  Missing data (n=159)
Fig 1 | Flow chart of patients through study
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(1.45 to 1.79; P<0.001). The C statistic was 0.67, indi-
cating good discriminative power of the models. The
hazard ratio for all cause death was 2.38 (2.12 to 2.67;
P<0.001). Analyses of the risk of the other secondary
outcomesgeneratedsimilarhazardratios.Thepropen-
sity score matched Kaplan-Meier analysis depicts the
increased risk of cardiovascular death and of readmis-
sion to hospital for myocardial infarction or stroke for
patients treated with or without proton pump inhibi-
tors (fig 2).
Sensitivity analyses
A time dependent propensity score matched Cox pro-
portional hazards regression sensitivity analysis
showednoincreaseinriskrelatedtoconcomitanttreat-
ment with aspirin and H2 receptor blockers (hazard
ratio 1.04, 95% confidence interval 0.79 to 1.38;
P=0.78) (fig 3). Interaction analyses between relevant
subgroupsofpatientsidentifiednointeractionbetween
treatment with proton pump inhibitors and outcomes.
Figure4showstheresultsofthesensitivityanalysesfor
high risk subgroups. The data did not provide any evi-
denceofdifferencesinriskrelatedtoage,sex,diabetes,
or heart failure.
Of the 4306 patients claiming at least one prescrip-
tion for protonpump inhibitors,1128 (26.2%) claimed
prescriptions for pantoprazole, 741 (17.2%) for lanso-
prazole, 1264 (29.4%) for omeprazole, 1043 (26.5%)
for esmoprazole, and 30 (0.01%) for rabeprazole. Of
the 15619 patients not treated with proton pump
inhibitors, 661 filled a prescription for H2 receptor
blockers. Results from the time dependent propensity
score matched Cox proportional hazards regression
analysis (see fig 3) showed no difference in risk asso-
ciated with different subtypes of proton pump inhibi-
tors. Rabeprazole was not included in this analysis as
the cohort was too small to generate reliableresults. In
the analysis testing for additional effect modification
related to concomitant use of ibuprofen or any non-
steroidal anti-inflammatory drug, no interaction was
found (P for interaction 0.93 and 0.92, respectively).
Using time dependent propensity score matching
conditional on baseline covariates predicting treat-
ment with proton pump inhibitors, the risk of gastro-
intestinal bleeding was analysed in patients treated
with aspirin and proton pump inhibitors; compared
with patients not receiving proton pump inhibitors
the risk of gastrointestinal bleeding was not reduced
(hazard ratio 1.02, 0.72 to 1.43; P=0.91).
When testing how large the effect of a potential
unmeasured confounder or combination of confoun-
ders would need to be to fully explain the increased
risk observed in patients treated with proton pump
inhibitors and aspirin, if an unmeasured confounder
was present in 20% of the population receiving proton
pump inhibitors, the confounder would have to
increase the risk by a factor of 4 to increase the hazard
ratio from 1.00 to 1.61 (fig 5). Further sensitivity ana-
lysis did not provide evidence of any difference
between high (150 mg) and low doses (75 to 100 mg)
of aspirin or between high and low doses of proton
pumpinhibitors(P=0.92and0.49,respectively,fordif-
ference in risk between high and low doses).
DISCUSSION
In aspirin treated patients with first time myocardial
infarction there was an increased risk of adverse
cardiovascular events associated with treatment using
proton pump inhibitors. This study was the first to
examine the clinical effects of a possible interaction
between aspirin and proton pump inhibitors by inves-
tigating the risk of adverse cardiovascular outcomes in
a nationwide unselected population of patients with
first time myocardial infarction.
Table 2 |Association between treatment with proton pump inhibitors and risk of adverse cardiovascular outcomes. Values are hazard ratios (95% confidence
intervals) unless stated otherwise
Outcome
Events during follow-up Time to dependent Cox
proportional hazards
regression P value
Propensity score matched
Cox proportional hazards
regression analysis P value
Patients not treated
with PPIs
Patients treated
with PPIs
Cardiovascular death,
myocardialinfarction,orstroke
2378 (15.2) 987 (22.9) 1.46 (1.33 to 1.61) <0.001 1.61 (1.45 to 1.79) <0.001
All cause death 1607 (10.3) 686 (15.9) 1.78 (1.60 to 1.98) <0.001 2.38 (2.12 to 2.67) <0.001
Cardiovascular death 1328 (8.5) 540 (12.5) 1.71 (1.51 to 1.92) <0.001 2.19 (1.92 to 2.49) <0.001
Myocardial infarction 1110 (7.1) 497 (11.5) 1.39 (1.20 to 1.62) <0.001 1.33 (1.13 to 1.56) <0.001
Stroke 1207 (7.7) 338 (7.9) 1.23 (1.03 to 1.47) 0.03 1.20 (0.99 to 1.46) 0.06
PPIs=proton pump inhibitors.
Use of proton pump inhibitors was included as time to dependent covariate.
Analysis time (days)
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Fig 2 | Propensity score matched Kaplan-Meier analysis of risk
of cardiovascular death, myocardial infarction, or stroke
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and proton pump inhibitors
Proton pump inhibitors protect the gastric mucosal
barrier by suppressing gastric acid production.
15
Under physiological acidic conditions, aspirin is
absorbed in its lipid state by passive diffusion across
the gastric mucosal membrane according to the pH
partition hypothesis.
16 Proton pump inhibitors exert
theirantacideffectbyinhibitingtheH
+/K
+exchanging
ATP-ase of the gastric parietal cells, thus raising intra-
gastric pH.
17 In fact the pH potentially rises above the
pKa (3.5) of acetylsalicylic acid (that is, the negative
logarithm of the acidic dissociation constant of a sub-
stance), thus reducing the lipophilicity of aspirin and
hence the absorption of the drug.
5 According to pre-
vious studies, such chemical changes might compro-
mise the bioavailability and therapeutic efficacy of
aspirin.
18-20Asall protonpumpinhibitorsaffectgastric
pHtoroughlythesameextent,theinteractionbetween
aspirin and these drugs is likely to represent a class
effect of proton pump inhibitors.
21 Along this line, a
recent study found that patients treated with proton
pump inhibitors had a reduced platelet response to
aspirin in terms of increased residual platelet aggrega-
tionandplateletactivationcomparedwithpatientsnot
taking proton pump inhibitors.
7
Is there a clinical effect of the observed ex vivo effect?
Currently,thedebateaboutthepossibilityofareduced
antiplatelet effect of clopidogrel in patients receiving
proton pump inhibitors and whether such possible
interaction has a significant clinical effect is
intense.
22-28 This uncertainty also raises the question
of whether the observed reduced ex vivo antiplatelet
effect of aspirin during treatment with proton pump
inhibitors has any clinical effect on cardiovascular
risk. Our study explored the clinical effect of such
potential interaction between aspirin and proton
pump inhibitors by investigating the risk of adverse
cardiovascular events in a nationwide unselected
aspirin treated population with first time myocardial
infarction. We found a significant effect of treatment
with proton pump inhibitors on cardiovascular out-
comes for patients treated with aspirin. This effect
was slightly higher in the propensity score matched
analysis, mainly reflecting the differences between
the two reference groups in the main analyses and the
propensity score matched analyses.
Possible explanations for the observed increased risk
There are several possible explanations for the
increased cardiovascular risk associatedwith concomi-
tant treatment with proton pump inhibitors in aspirin
treated patients. Firstly, the increased risk results from
modification of intragastric pH, causing reduced bio-
availability of aspirin and thereby increased residual
platelet aggregation and platelet activation, as pre-
viously reported.
7 Secondly, treatment with proton
pump inhibitors itself increases the risk of adverse
cardiovascular outcomes owing to an as yet unknown
physiological or biological pathway. Thirdly, the
increased risk of adverse cardiovascular events related
to concomitant treatment with aspirin and proton
pump inhibitors is caused by unmeasured differences
inbaselinecomorbidities.Ifthiswasthecase,however,
our calculations showed that if an unmeasured con-
founder or a combination of confounders was present
in 20% of the cohort treated with proton pump inhibi-
tors,the confounderwould havetoincreasethe risk by
a factor of 4 to explain the increased risk observed in
our study. Existence of such confounders or combina-
tion of confounders is unlikely, but not impossible,
since we had no information on other important risk
factors such as lipid levels, body mass index, or smok-
ing.Smokingisanimportantconfounderasitincreases
theriskofpepticulcersandthereforechannelsapatient
towards treatment with proton pump inhibitors, but
Pantoprazole
Omeprazole
Lansoprazole
Esmoprazole
H2 receptor blocker
Any proton pump inhibitor
No proton pump inhibitor (reference)
0.8 1.0 1.5 2.0
Hazard ratio (95% CI)
Fig 3 | Time dependent adjusted propensity score matched
Cox proportional hazard analysis of risk of cardiovascular
death, myocardial infarction, or stroke for subtypes of proton
pump inhibitors and H2 receptor blockers
Table 3 |Propensity score matched model results of probability of treatment with proton
pump inhibitors during one year of follow-up
Characteristics Estimates Odds ratio (95% CI) P value
Age −0.01 0.99 (0.95 to 1.03) 0.56
Year 0.17 1.18 (1.17 to 1.20) <0.001
Male sex −0.17 0.85 (0.79 to 0.91) <0.001
Income group −0.08 0.92 (0.89 to 0.95) <0.001
Percutaneous coronary intervention 0.22 1.25 (1.07 to 1.45) 0.005
Medical condition:
Shock 0.46 1.59 (1.17 to 2.17) 0.003
Diabetes with complications −0.18 0.83 (0.69 to 1.00) 0.05
Peptic ulcer 2.18 8.86 (6.64 to 11.82) <0.001
Pulmonary oedema −0.16 0.85 (0.63 to 1.15) 0.30
Cerebral vascular disease 0.24 1.27 (1.09 to 1.48) 0.003
Cancer 0.43 1.53 (0.94 to 2.48) 0.08
Cardiac dysrhythmias −0.08 0.92 (0.82 to 1.03) 0.14
Acute renal failure 0.61 1.85 (1.29 to 2.64) <0.001
Chronic renal failure 0.94 2.58 (1.93 to 3.46) <0.001
Prescribed drugs:
Loop diuretics 0.33 1.39 (1.28 to 1.50) <0.001
Spironolacton 0.14 1.16 (1.03 to 1.29) 0.01
Statin −0.05 0.95 (0.88 to 1.03) 0.25
β blocker −0.01 0.99 (0.92 to 1.08) 0.88
ACE inhibitor −0.07 0.93 (0.88 to 0.99) 0.01
Antidiabetes drugs 0.10 1.10 (0.98 to 1.24) 0.12
Vitamin K antagonist −0.09 0.91 (0.80 to 1.05) 0.19
ACE=angiotensin converting enzyme.
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infarction and death. Importantly, any such confound-
ing would also affect patients receiving H2 receptor
blockers, which have identical therapeutic indications
asprotonpumpinhibitors.Notably,wedidnotobserve
an increased risk associated with treatment using H2
receptor blockers, supporting the hypothesis of the
unique effects of proton pump inhibitors on the anti-
thromboticpropertiesofaspirin.Finally,thepossibility
remainsthattheincreasedcardiovascularriskobserved
in patients receiving concomitant treatment with
aspirin and proton pump inhibitors was caused by a
combination of the other three potential explanations.
Clinical relevance for the suggested clopidogrel-proton
pump inhibitor interaction
If the findings of this study are seen in the light of the
recent discussion of the potential interaction between
proton pump inhibitors and clopidogrel, they raise an
important question: whether the putative interaction
between clopidogrel and proton pump inhibitors
may be explained, at least in part, by an interaction
between aspirin and proton pump inhibitors, as vir-
tually all patients treated with clopidogrel also receive
aspirin. Interestingly, we recently found an increased
cardiovascular risk associated with proton pump inhi-
bitors independent of clopidogrel use.
26
Other analyses
Recent studies have shown an increased risk of gastro-
intestinal bleeding in patients receiving dual anti-
platelet treatment without proton pump inhibitors,
emphasising the importance of evaluating the cardio-
vascular safety of concomitant treatment with proton
pumpinhibitors.
29Wewerenotabletoshowareduced
risk of gastrointestinal bleeding in aspirin treated
patients receiving proton pump inhibitors. In Den-
mark, proton pump inhibitors are not prescribed rou-
tinely for patients receiving aspirin but mainly for
patients with a clear therapeutic indication, such as
peptic ulcer disease. Thus the aspirin group treated
withprotonpumpinhibitorsinourstudywasprobably
confounded by indication for proton pump inhibitors
and consequently had a higher risk of bleeding than
patients in countries where guidelines recommend
routine use of proton pump inhibitors in combination
with dual antiplatelet therapy. This confounding may
explain why we were not able to show any effect of
treatment with proton pump inhibitors on gastro-
intestinal bleeding. Other studies have found that con-
comitant treatment with non-steroidal anti-
inflammatorydrugs,especially ibuprofen, antagonises
theirreversibleplateletinhibitioninducedbyaspirin.
30
We found no additional effect modification related to
concomitant use of ibuprofen or any non-steroidal
anti-inflammatory drugs in our study.
In addition, we did not observe any differences in
risk between subtypes of proton pump inhibitors or
high or low doses of proton pump inhibitors and
aspirin. Sensitivity analyses did not provide evidence
of differences in risk related to sex, age, or presence of
heart failure or diabetes.
Strengths and limitations of the study
Important strengths of the study include the large size
of our study sample and the fact that it was based on a
nationwide unselected cohort of patients after myo-
cardial infarction in a clinical setting. The Danish
national patient registry includes all hospital admis-
sionsinDenmarkandisthereforenotaffectedbyselec-
tion bias from, for example, selective inclusion of
specific hospitals, health insurance systems, or age
groups. The concordance between drug dispensing
and drug use is likely to be high, since reimbursement
ofdrugexpensesisonlypartialandmostdrugs,includ-
ing proton pump inhibitors, were not available over
the counter in Denmark during the study period.
Exceptions were aspirin and H2 receptor blockers.
This explains why so few patients filled prescriptions
for aspirin during the first 30 days after discharge.
Because adherence to drugs has been documented to
be high in Danish patients after myocardial infarction
(forexample,85%adherencetostatins12monthsafter
myocardial infarction),
8 we assume that most patients
who did not fill a prescription for aspirin were treated
with over the counter aspirin, even though we cannot
completely rule out the possibility of selection bias.
Additional limitations of the study are that
>70 years
≤70 years
Male
Female
Diabetes
No diabetes
Heart failure
No heart failure
Any proton pump inhibitor
No proton pump inhibitor (reference)
1.0 1.2 1.4 1.8
Hazard ratio (95% CI)
Fig 4 | Time dependent adjusted Cox proportional hazard
analysis of cardiovascular death, myocardial infarction, or
stroke in high risk patient subgroups treated with proton
pump inhibitors. Diabetes=requiring glucose lowering drugs
Association between confounder and disease outcome (RRCD)
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groups should be made with caution and that we did
not have any information on the indication for treat-
ment with proton pump inhibitors.
Conclusions
In this study of a large unselected nationwide popula-
tion we found that use of proton pump inhibitors in
aspirin treated patients with first time myocardial
infarction was associated with an increased risk of
adverse cardiovascular events. The increased risk was
not observed in patients treated with H2 receptor
blockers. It is unlikely, but not impossible, that the
increasedcardiovascularriskassociatedwithconcomi-
tant use of aspirin and proton pump inhibitors is
caused by unmeasured confounders. Focus on this
area, includingthe implication of thisstudyfor the dis-
cussion on clopidogrel and proton pump inhibitors is
warranted owing to the large clinical implications of a
possible interaction between proton pump inhibitors
and aspirin. Randomised prospective studies as well
as observational studies based on other populations
are needed.
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